Latest Advances in Gastroesophageal Cancers: Community Workshops for the Multidisciplinary Team

Register now for this live, 1-hour workshop to gain expert insights on incorporating immunotherapy and new targeted and histology-agnostic treatment options into the care of patients with gastric and gastroesophageal junction cancers. After the meeting, download the associated slideset for use in your clinic.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


  • Current advances in immunotherapy in early-stage gastroesophageal junction (GEJ) cancer
  • Selection of therapy for previously untreated gastric/GEJ cancers
  • Incorporating new therapeutic strategies and agents available for previously treated patients in the second-line and beyond
  • Identification and management of common and serious adverse events associated with immunotherapy and targeted therapy
  • Review of ongoing clinical trials
  • Audience question & answer session


Date / Time
Event Details


Program Chair
Jaffer Ajani, MD

Professor of Medicine
Department of GI Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Program Chair
David H. Ilson, MD, PhD

Professor of Medicine
Weill Cornell Medical College
Attending Physician
Memorial Sloan Kettering Cancer Center
New York, New York

Samuel Klempner, MD

Associate Professor
Division of Hematology-Oncology
Department of Medicine
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

Kelsey Klute, MD

Anwaar Saeed, MD

Nataliya Uboha, MD, PhD

Associate Professor
University of Wisconsin, Carbone Cancer Center
Madison, Wisconsin

Zev A. Wainberg, MD

Assistant Professor, Hematology/Oncology
University of California, Los Angeles
Los Angeles, California

Goal Statement
The goal of this activity is to improve the knowledge, confidence, competence of community care teams in integrating the available clinical data, guidelines, and expert recommendations into the care of their patients with gastroesophageal cancers.

Target Audience
This program is intended for nurses, pharmacists, oncologists and other healthcare professionals involved in the treatment of patients with gastroesophageal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify appropriate patients with completely resected esophageal or GEJ cancer who are candidates for adjuvant immunotherapy
  • Plan frontline immune checkpoint inhibitor–based therapy for appropriate patients based on recent clinical data and current indications in esophageal squamous cell carcinoma
  • Develop optimal sequencing of agents for patients with HER2-positive gastric/GEJ cancer
  • Incorporate histology-agnostic targeted therapy into treatment plans using newly approved indications
  • Manage treatment-related symptoms for patient with gastric, GEJ, or esophageal squamous cell carcinoma


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-027-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.